Log in

NASDAQ:KRTXKaruna Therapeutics Stock Price, Forecast & News

-1.19 (-1.19 %)
(As of 07/9/2020 04:00 PM ET)
Today's Range
Now: $98.99
50-Day Range
MA: $97.51
52-Week Range
Now: $98.99
Volume147,100 shs
Average Volume304,572 shs
Market Capitalization$2.59 billion
P/E RatioN/A
Dividend YieldN/A
Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, primarily focuses on developing novel therapies to address disabling neuropsychiatric conditions characterized by significant unmet medical needs. The company's lead product candidate is KarXT, an oral modulator that is in Phase II clinical trial for the treatment of acute psychosis in patients with schizophrenia, as well as in Phase Ib clinical trial for the treatment of central nervous system disorders, such as cognitive and negative symptoms, Alzheimer's, and pain. It also focuses on developing other muscarinic-targeted drug candidates. Karuna Pharmaceuticals, Inc. has a license agreement with Eli Lilly and Company; and patent license agreement with PureTech Health LLC. The company was formerly known as Karuna Pharmaceuticals, Inc. and changed its name to Karuna Therapeutics, Inc. in March 2019. Karuna Therapeutics, Inc. was founded in 2009 and is headquartered in Boston, Massachusetts. Karuna Therapeutics, Inc. operates as a subsidiary of PureTech Health plc.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.48 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:KRTX



Sales & Book Value

Annual SalesN/A
Book Value$16.65 per share


Net Income$-43,960,000.00


Market Cap$2.59 billion
Next Earnings Date8/13/2020 (Estimated)
OptionableNot Optionable

Receive KRTX News and Ratings via Email

Sign-up to receive the latest news and ratings for KRTX and its competitors with MarketBeat's FREE daily newsletter.

Karuna Therapeutics (NASDAQ:KRTX) Frequently Asked Questions

How has Karuna Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Karuna Therapeutics' stock was trading at $78.79 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, KRTX shares have increased by 25.6% and is now trading at $98.99. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Karuna Therapeutics?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Karuna Therapeutics in the last year. There are currently 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Karuna Therapeutics.

When is Karuna Therapeutics' next earnings date?

Karuna Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Karuna Therapeutics.

How were Karuna Therapeutics' earnings last quarter?

Karuna Therapeutics (NASDAQ:KRTX) issued its earnings results on Thursday, May, 7th. The company reported ($0.33) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.38) by $0.05. View Karuna Therapeutics' earnings history.

What price target have analysts set for KRTX?

11 brokers have issued 1-year price targets for Karuna Therapeutics' stock. Their forecasts range from $28.00 to $140.00. On average, they anticipate Karuna Therapeutics' stock price to reach $117.73 in the next year. This suggests a possible upside of 18.9% from the stock's current price. View analysts' price targets for Karuna Therapeutics.

Has Karuna Therapeutics been receiving favorable news coverage?

Press coverage about KRTX stock has trended neutral this week, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Karuna Therapeutics earned a news sentiment score of 0.5 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View the latest news about Karuna Therapeutics.

Are investors shorting Karuna Therapeutics?

Karuna Therapeutics saw a increase in short interest in June. As of June 30th, there was short interest totaling 1,130,000 shares, an increase of 10.8% from the June 15th total of 1,020,000 shares. Based on an average daily volume of 249,600 shares, the days-to-cover ratio is presently 4.5 days. Currently, 7.3% of the shares of the stock are sold short. View Karuna Therapeutics' Current Options Chain.

Who are some of Karuna Therapeutics' key competitors?

What other stocks do shareholders of Karuna Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Karuna Therapeutics investors own include NVIDIA (NVDA), Micron Technology (MU), Roku (ROKU), AbbVie (ABBV), Walt Disney (DIS), Advanced Micro Devices (AMD), Alibaba Group (BABA), Applied Materials (AMAT), Marvell Technology Group (MRVL) and salesforce.com (CRM).

Who are Karuna Therapeutics' key executives?

Karuna Therapeutics' management team includes the following people:
  • Dr. Steven M. Paul M.D., Chairman & CEO (Age 68)
  • Dr. Andrew Craig Miller, Founder, COO & Director
  • Dr. Edmund P. Harrigan M.D., Director (Age 66)
  • Dr. Richard Kavoussi, Chief Medical Officer
  • Dr. Alan Breier, Chief Clinical Advisor

When did Karuna Therapeutics IPO?

(KRTX) raised $70 million in an IPO on Friday, June 28th 2019. The company issued 4,400,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs, Citigroup and Wells Fargo Securities acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What is Karuna Therapeutics' stock symbol?

Karuna Therapeutics trades on the NASDAQ under the ticker symbol "KRTX."

How do I buy shares of Karuna Therapeutics?

Shares of KRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Karuna Therapeutics' stock price today?

One share of KRTX stock can currently be purchased for approximately $98.99.

How big of a company is Karuna Therapeutics?

Karuna Therapeutics has a market capitalization of $2.59 billion. The company earns $-43,960,000.00 in net income (profit) each year or ($3.68) on an earnings per share basis. Karuna Therapeutics employs 13 workers across the globe.

What is Karuna Therapeutics' official website?

The official website for Karuna Therapeutics is karunatx.com.

How can I contact Karuna Therapeutics?

Karuna Therapeutics' mailing address is 33 ARCH STREET SUITE 3110, BOSTON MA, 02110. The company can be reached via phone at 857-449-2244 or via email at [email protected]

This page was last updated on 7/10/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.